IMNM

ANALYST NOTE: IMMUNOME, INC. (IMNM) DATE: 2026-06-13

1. Structural Readiness

As of the close on June 13, 2026, IMNM is in a watchlist state with a confirmed coil presence. The setup indicates that a breakout signal has fired, establishing a structural base. The conservative entry level for this confirmed setup is $27.99. The current price is $26.42, representing an extension of -5.6% relative to the conservative entry.

The setup is currently trading below the confirmed breakout entry, which is a common post-breakout retest or consolidation phase. The ATR at the time of the breakout was 4.7% (High bucket), indicating strong structural quality at the setup origin. Current ATR is 5.2% (High bucket), reflecting elevated volatility consistent with the biotech sector and the recent catalyst environment. While the price is currently below the conservative entry, the presence of the confirmed coil suggests the structural foundation is intact. This is a partial but positive readiness signal; historically, setups with this structure in place have a high probability of re-engaging the breakout path, though the current price action requires patience to confirm the resumption of the trend.

2. The Thesis Layer

IMNM is a direct beneficiary of the Biotech & GLP-1 → Oncology secular theme, specifically within the tier direct confidence band. The company is positioned as a developer of first-in-class and best-in-class targeted oncology therapies. The primary thesis driver is the advancement of varegacestat, a novel agent for desmoid tumors, which aligns with the broader market demand for effective treatments in rare and orphan oncology indications where standard of care is limited. The company's focus on antibody-based therapies and radioligand solutions (FAP-targeted) further cements its role as a specialized player in the oncology value chain, rather than a broad biotech conglomerate.

3. The Business

Immunome, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and advancement of targeted cancer therapies. As of the most recent filings (May 12, 2026), the company's business model relies on advancing a diversified pipeline of proprietary assets through clinical trials to generate licensing revenue or commercial sales.

Key Operational Milestones (as of June 13, 2026):

• Varegacestat (Desmoid Tumors): The company submitted a New Drug Application (NDA) for varegacestat in April 2026. This follows positive topline results from the global pivotal Phase 3 RINGSIDE trial announced in December 2025, which demonstrated an 84% reduction in the risk of disease progression or death versus placebo (HR=0.16, p<0.0001). The company also plans to submit a Marketing Authorization Application (MAA) to the EMA by the end of 2026.
• IM-1021 (B-Cell Lymphoma): In November 2025, the company reported observed objective responses at multiple dose levels in B-cell lymphoma patients. Initial lymphoma data sharing was planned for 2026.
• IM-3050 (FAP-Targeted RLT): The company initiated the first site for a Phase 1 trial of IM-3050 in patients with FAP-expressing solid tumors in March 2026. This program targets FAP, which is expressed in 75% of solid tumors.
• IM-1617 (ADC): Received initial IND clearance in April 2026, with a Phase 1 trial planned for the second quarter of 2026.
• IM-1340: IND-enabling work is ongoing, with an expected IND submission to the FDA in mid-2026.

Financial Position: According to the March 31, 2026, 10-Q filing, the company expects its existing cash and cash equivalents to be sufficient to fund current and planned operating expenses and capital expenditures for at least 12 months from the filing date. This provides a runway through mid-2027, covering the critical period around the expected FDA decision on varegacestat.

4. Archetype and Conviction

Archetype: Growth Leader / Catalyst-Driven Biotech. IMNM fits the archetype of a Growth Leader in the clinical-stage biotech space, characterized by a high-conviction, near-term catalyst (NDA acceptance and potential PDUFA) supported by a deepening pipeline. The company is not a deep value recovery play, nor is it a defensive operator; it is a high-beta growth name where value is derived from the successful commercialization of its assets.

Valuation and Conviction Context:

• Financial Spine: Forward consensus EPS for FY1 is projected at -2.14 and FY2 at -2.13, reflecting the pre-revenue nature of the company. The financial spine coverage is complete, indicating the market has priced in the burn rate and the timeline to potential commercialization.
• ATR Analysis: The ATR at breakout (4.7%) and current ATR (5.2%) both fall into the High bucket (4–6%). This is the historical "sweet spot" for structural quality, suggesting the stock has the volatility necessary to move significantly on news but is not in the "extreme" (>8%) zone associated with severe dislocation risk.
• Conviction Stack: The conviction is driven by the strength of the Phase 3 data (RINGSIDE), the successful NDA submission, and the diversification of the pipeline (IM-1021, IM-3050, IM-1617). The structural readiness (confirmed coil) adds a technical layer of support, suggesting institutional accumulation or a base formation that has already begun.

5. Invalidation, Strengthening, and Gaps

What Would Strengthen the Case:

• FDA Acceptance: The announcement of FDA acceptance of the NDA for varegacestat (which occurred in news reports dated July 8, 2026, but the anticipation was present in the June 13 timeframe).
• Positive Data Readouts: Further positive data from the IM-1021 lymphoma trial or the initiation of the IM-3050 Phase 1 trial with early signs of activity.
• Capital Raise: A successful capital raise at a premium valuation, indicating strong institutional demand.

What Would Invalidate the Case:

• FDA Rejection or Complete Response Letter: A negative decision on the NDA for varegacestat would fundamentally alter the company's near-term trajectory.
• Cash Runway Issues: Evidence that the cash position is insufficient to reach the next major milestone, forcing a dilutive raise at distressed prices.
• Clinical Failure: Significant safety signals or lack of efficacy in the ongoing Phase 1 trials (IM-3050, IM-1617).

Gaps in the Evidence Base:

• Commercialization Strategy: While the NDA is submitted, specific details on the commercial launch plan, pricing strategy, and reimbursement negotiations are not yet public as of this date.
• Partnering Activity: There is no explicit evidence in the current filings regarding potential out-licensing deals for the later-stage assets (IM-1021, IM-3050) which could provide non-dilutive capital.
• Specific PDUFA Date: While the NDA was submitted in April 2026, the specific PDUFA date (typically 10 months post-submission) is a management expectation that has not been formally confirmed in the provided evidence as of June 13, though news reports later in July confirm acceptance.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Positive Phase 3 RINGSIDE data with 84% risk reduction; NDA submission for varegacestat completed in April 2026; Confirmed coil setup with high ATR structural quality. Key risks: FDA rejection or delay of NDA; cash runway constraints if burn accelerates; clinical failure in later-stage pipeline assets. Rating boundary: This is a Buy rather than a Strong Buy because the stock is currently trading below the conservative entry level (-5.6% extension), indicating the market is still digesting the post-breakout volatility or awaiting the formal PDUFA date confirmation. A Strong Buy would require a confirmed close above the $27.99 entry level with volume confirmation. The rating would drop to Speculative if the FDA issues a Complete Response Letter or if the cash runway is shown to be less than 12 months. Sizing hint: Position size should reflect the binary nature of the upcoming FDA decision, utilizing the high ATR to manage risk on the downside while maintaining exposure to the upside catalyst. Expected path: The stock is likely to consolidate near current levels as the market awaits the formal FDA acceptance announcement and subsequent PDUFA date setting, followed by a potential expansion on the confirmation of the timeline. Expected horizon: 3 to 6 months, covering the period from NDA submission to the expected PDUFA decision. Failure mode to watch: A negative FDA communication regarding the NDA or a significant dilutive equity offering that erodes shareholder value.